Leukemia infusion treatment means giving anti-leukemia medicines directly into a vein, usually through a drip or a central line, rather than as pills. It includes intravenous chemotherapy, antibody drugs, and some immunotherapies, and it is the main way acute leukemias are treated. Below I cover what an infusion session involves, which drugs are given this way, how the lines work, and what is changing in the field.
What Is Leukemia Infusion Treatment?
In an infusion, medicine is delivered into the bloodstream over minutes, hours, or sometimes several days of continuous flow. Because the drug reaches the circulation directly, its dose and timing can be controlled precisely. That matters when a leukemia is growing fast and the aim is to cut the number of leukemic cells quickly.
Infusions are the backbone of treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Some chronic leukemias are managed mostly with oral drugs, though infusions still have a role in certain situations. For a wider view of how infusion fits alongside other options, see our overview of leukemia infusion treatment and advanced strategies.
Why Some Leukemias Need Infusion and Others Do Not
Leukemia starts when blood-forming cells in the bone marrow acquire genetic changes that let them multiply out of control. The behavior of those changes largely decides the treatment route.
In chronic myeloid leukemia (CML), the BCR-ABL1 fusion gene produces an overactive enzyme that oral tyrosine kinase inhibitors such as imatinib can block. Most people with CML therefore take tablets, not infusions, as outlined in our guide to the diagnosis and management of chronic myelogenous leukemia.
Rarer conditions follow their own logic. In chronic neutrophilic leukemia, mutations in the CSF3R gene drive overgrowth of neutrophils, and treatment is tailored to that biology. Acute leukemias, by contrast, usually need intensive intravenous therapy from the start.
Common Drugs Given by Infusion
Many different agents are delivered intravenously. The table below groups the main types you are likely to hear about.
| Drug class | Examples | Typical use |
|---|---|---|
| Conventional chemotherapy | Cytarabine, daunorubicin, idarubicin, vincristine | Induction and consolidation in AML and ALL |
| Monoclonal antibodies | Rituximab, obinutuzumab | CD20-positive leukemias such as CLL, often with other drugs |
| Antibody-drug conjugates | Inotuzumab ozogamicin, gemtuzumab ozogamicin | CD22-positive ALL; CD33-positive AML |
| Bispecific T-cell engagers | Blinatumomab | B-cell ALL, including relapsed disease and residual disease |
| Cellular therapy | CAR T-cells | Relapsed or refractory B-cell ALL in selected patients |
| Hypomethylating agents | Azacitidine, decitabine | Older or less fit patients with AML (IV or under the skin) |
Chemotherapy drugs kill rapidly dividing cells, which is why they also affect hair, the lining of the mouth and gut, and normal blood counts. Antibody-based drugs are more selective. They lock onto a marker on the leukemia cell surface and either flag it for the immune system or deliver a toxin straight to it.
What to Expect During an Infusion
Most people receiving intensive leukemia treatment have a central venous catheter. This might be a PICC line in the arm, a tunneled line in the chest, or an implanted port. These lines protect smaller veins from irritating drugs and make blood tests and transfusions easier.
A typical session follows a similar pattern:
- Blood tests confirm that counts, kidney function, and liver function are safe for treatment.
- Premedications such as anti-nausea drugs, and for antibodies, antihistamines or steroids, are given.
- The drug runs through a pump at a set rate while nurses check vital signs.
- After the infusion, the line is flushed and plans are made for the next dose.
Some regimens, such as the seven-day cytarabine infusion in AML, run continuously in hospital. Others are short day-unit visits. Blinatumomab is given as a continuous infusion over weeks through a small portable pump.
Side Effects and How They Are Managed
Side effects depend on the drug. Chemotherapy commonly causes low blood counts, infection risk, fatigue, nausea, mouth sores, and hair loss. Vincristine can cause tingling or numbness in the hands and feet. Anthracyclines need heart monitoring, as they can affect heart muscle at higher cumulative doses.
Antibody and immune therapies bring different risks. Infusion reactions, such as fever, chills, or a drop in blood pressure, are most likely with the first dose. Blinatumomab and CAR T-cells can cause cytokine release syndrome and neurological side effects, so patients are closely monitored at the start of treatment.
Hematologic support is a large part of care. Patients often need red cell and platelet transfusions, and preventive antibiotics or antifungals may be used while the neutrophil count is low. Tumor lysis syndrome, a chemical imbalance caused by many leukemia cells breaking down at once, is prevented with fluids and medication.
Advancing Leukemia Infusion Treatment
Research is making infusion treatment more targeted and, in some cases, less toxic. Key areas include:
- Combining targeted drugs with chemotherapy: adding agents like FLT3 inhibitors to intensive regimens for patients with matching mutations.
- Immunotherapy earlier in treatment: using blinatumomab or inotuzumab in earlier treatment lines rather than only at relapse.
- Measurable residual disease (MRD) guidance: using very sensitive tests to decide whether to intensify or reduce treatment.
- Next-generation CAR T-cells: work aimed at extending cellular therapy to more leukemia types and reducing side effects.
Clinical trials continue to test new agents and combinations, and joining a trial is worth discussing with your team at any stage. More background is in our leukemia guide.
When to See a Doctor During Treatment
Call your treatment team straight away if you have a temperature of 38°C (100.4°F) or higher, shaking chills, new bleeding or widespread bruising, shortness of breath, confusion, or redness, swelling, or pain around your line. During periods of low neutrophils, fever can be the only sign of a serious infection and needs same-day assessment.
Frequently Asked Questions
How long does a leukemia infusion take?
It varies from a few minutes for a push injection to several hours for antibody drugs. Some regimens run continuously for days or weeks. Your team will give you a schedule for each cycle.
Is infusion treatment better than oral treatment?
Neither is better overall; the right route depends on the leukemia type. Acute leukemias usually need intravenous therapy, while CML is typically controlled with oral tyrosine kinase inhibitors. Some patients receive both.
Do I need a port or central line?
Most patients on intensive or long-term infusion therapy benefit from one. It reduces damage to arm veins and makes frequent blood tests easier. Your team will recommend the type that suits your treatment plan.
Can I go home after an infusion?
Many infusions are given in a day unit, and you go home the same day. Intensive induction chemotherapy for acute leukemia usually requires a hospital stay because of low blood counts and infection risk.
